BR0214672A - Inibidores de fosfolipase citosólica a2 - Google Patents

Inibidores de fosfolipase citosólica a2

Info

Publication number
BR0214672A
BR0214672A BR0214672-0A BR0214672A BR0214672A BR 0214672 A BR0214672 A BR 0214672A BR 0214672 A BR0214672 A BR 0214672A BR 0214672 A BR0214672 A BR 0214672A
Authority
BR
Brazil
Prior art keywords
inhibitors
phospholipase
cytosolic phospholipase
compounds
cytosolic
Prior art date
Application number
BR0214672-0A
Other languages
English (en)
Inventor
John Caedmon Mckew
Steve Vik-Kai Tam
James Donald Clark
Katherine Lin Lee
Lihren Chen
Oaresh Thakker
Fuk-Wah Sum
Mark Leo Behnke
Baihua Hu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BR0214672A publication Critical patent/BR0214672A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Abstract

"INIBIDORES DE FOSFOLIPASE CITOSóLICA A2". A presente invenção refere-se a compostos indol substituídos de fórmula geral (I) (I) e formas de sal farmaceuticamente aceitáveis do mesmo e métodos para usar os compostos como inibidores da atividade de várias enzimas fosfolipase, particularmente enzimas fosfolipase A~ 2~ e para o tratamento médico, prevenção e inibição de dor e inflamação.
BR0214672-0A 2001-12-03 2002-12-02 Inibidores de fosfolipase citosólica a2 BR0214672A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33459101P 2001-12-03 2001-12-03
US33458801P 2001-12-03 2001-12-03
US33460501P 2001-12-03 2001-12-03
US41966402P 2002-10-18 2002-10-18
PCT/US2002/038311 WO2003048122A2 (en) 2001-12-03 2002-12-02 Inhibitors of cytosolic phospholipase a2

Publications (1)

Publication Number Publication Date
BR0214672A true BR0214672A (pt) 2004-10-19

Family

ID=27502498

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214672-0A BR0214672A (pt) 2001-12-03 2002-12-02 Inibidores de fosfolipase citosólica a2

Country Status (25)

Country Link
EP (1) EP1451154B1 (pt)
JP (1) JP4657605B2 (pt)
KR (1) KR100973665B1 (pt)
CN (1) CN100503566C (pt)
AR (1) AR037684A1 (pt)
AT (1) ATE384045T1 (pt)
AU (1) AU2002351182B2 (pt)
BR (1) BR0214672A (pt)
CA (1) CA2469138C (pt)
CO (1) CO5580763A2 (pt)
CY (1) CY1107383T1 (pt)
DE (1) DE60224707T2 (pt)
DK (2) DK1451154T3 (pt)
EC (1) ECSP045131A (pt)
ES (2) ES2300490T3 (pt)
HK (2) HK1065799A1 (pt)
HU (1) HUP0402577A3 (pt)
IL (2) IL162052A0 (pt)
IN (1) IN2005KO00312A (pt)
NO (1) NO327256B1 (pt)
NZ (1) NZ533269A (pt)
PL (1) PL370445A1 (pt)
PT (1) PT1451154E (pt)
TW (1) TWI334778B (pt)
WO (1) WO2003048122A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605156B2 (en) 2001-12-03 2009-10-20 Wyeth Methods for the use of inhibitors of cytosolic phospholipase A2
US7713964B2 (en) 2001-12-03 2010-05-11 Wyeth Llc Methods for treating asthmatic conditions
TW200510305A (en) 2003-07-25 2005-03-16 Wyeth Corp Process for the preparation of CPLA2 inhibitors
ATE382035T1 (de) 2003-11-17 2008-01-15 Wyeth Corp Verfahren zur herstellung von n-substituierten phthalimiden
HN2004000536A (es) * 2003-12-16 2009-02-18 Wyeth Corp Un procediemiento de sintesis para la alquilacion reductiva de la posicon c-3 de indoles
AR048239A1 (es) 2004-02-25 2006-04-12 Wyeth Corp Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo e intermediarios de sintesis de los mismos
US20050244367A1 (en) * 2004-05-03 2005-11-03 Ilypsa, Inc. Phospholipase inhibitors localized in the gastrointestinal lumen
AR053410A1 (es) * 2004-08-19 2007-05-09 Wyeth Corp Proceso para la sintesis de indoles n-alquilados c-2, c-3 sustituidos. compuestos intermediarios
WO2006108424A2 (en) 2005-04-13 2006-10-19 Astion Pharma A/S Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
TW200718687A (en) 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
KR20080027868A (ko) 2005-07-21 2008-03-28 와이어쓰 설폰산염으로부터 설포닐 할라이드 및 설폰아미드의 합성방법
MX2008005666A (es) 2005-11-03 2009-03-02 Ilypsa Inc Compuestos multivalentes de indol y uso de los mismos como inhibidores de fosfolipasa-a2.
FR2899471A1 (fr) * 2006-04-06 2007-10-12 Pasteur Institut Utilisation d'au moins un inhibiteur de la phospholipase a2 cytosolique comme medicament pour le traitement des maladies respiratoires
WO2007140317A2 (en) * 2006-05-26 2007-12-06 Wyeth Use of inhibitors of cytosolic ph0sph0lipase a2 in the treatment of thrombosis
JP2010508303A (ja) * 2006-10-31 2010-03-18 ワイス エルエルシー ホスホリパーゼ酵素阻害剤の液体製剤
US20100056520A1 (en) * 2006-10-31 2010-03-04 Frances Anne Donahue Formulations of phospholipase enzyme inhibitors
JP5164972B2 (ja) * 2007-03-29 2013-03-21 第一三共株式会社 ｃＰＬＡ２阻害活性を有するインドール誘導体およびその用途並びに製造方法
CN102015656A (zh) 2008-04-28 2011-04-13 旭化成制药株式会社 苯丙酸衍生物及其用途
EP2488025A4 (en) * 2009-10-15 2013-04-03 Childrens Medical Center SEPIAPTERIC INTREDUCTASE INHIBITION FOR PAIN TREATMENT
EP2614144B1 (en) 2010-09-08 2015-07-22 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
SK12742000A3 (sk) * 1998-02-25 2001-05-10 Genetics Institute, Inc. Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie
NZ506329A (en) * 1998-02-25 2004-01-30 Inst Genetics Llc Inhibitors of phospholipase enzymes

Also Published As

Publication number Publication date
WO2003048122A2 (en) 2003-06-12
CO5580763A2 (es) 2005-11-30
JP4657605B2 (ja) 2011-03-23
CA2469138C (en) 2012-04-17
HUP0402577A3 (en) 2011-05-30
NO327256B1 (no) 2009-05-25
AU2002351182B2 (en) 2009-01-15
AU2002351182A1 (en) 2003-06-17
AR037684A1 (es) 2004-12-01
NO20042679L (no) 2004-06-25
HUP0402577A2 (hu) 2005-03-29
HK1113798A1 (en) 2008-10-17
HK1065799A1 (en) 2005-03-04
PL370445A1 (en) 2005-05-30
DE60224707D1 (de) 2008-03-06
CN1617855A (zh) 2005-05-18
TW200301695A (en) 2003-07-16
KR100973665B1 (ko) 2010-08-04
EP1451154B1 (en) 2008-01-16
JP2005515997A (ja) 2005-06-02
IN2005KO00312A (pt) 2015-08-14
NZ533269A (en) 2006-03-31
ES2401454T3 (es) 2013-04-19
CN100503566C (zh) 2009-06-24
EP1451154A2 (en) 2004-09-01
TWI334778B (en) 2010-12-21
DK1892239T3 (da) 2013-03-25
CY1107383T1 (el) 2012-12-19
IL162052A (en) 2013-04-30
ECSP045131A (es) 2004-07-23
IL162052A0 (en) 2005-11-20
KR20050044661A (ko) 2005-05-12
PT1451154E (pt) 2008-04-21
DE60224707T2 (de) 2009-02-26
WO2003048122A3 (en) 2003-09-18
CA2469138A1 (en) 2003-06-12
DK1451154T3 (da) 2008-05-19
ES2300490T3 (es) 2008-06-16
ATE384045T1 (de) 2008-02-15

Similar Documents

Publication Publication Date Title
BR0214672A (pt) Inibidores de fosfolipase citosólica a2
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
DK1611088T3 (da) Hydroxymater som terapeutiske midler
NO20061253L (no) Acetylenderivater som inhibitorer av histon deacetylase
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
YU21702A (sh) Supstituisani indoli za moduliranje nfkb aktivnosti
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
BR0317020A (pt) Derivados de hidroxietilamina para o tratamento de doença de alzheimer
ATE408601T1 (de) Fredericamycin-derivate
WO2002046129A3 (en) Inhibitors of histone deacetylase
DK1590340T3 (da) Histondeacetylase-inhibitorer
DE60143520D1 (de) Inhibitoren der histon-deacetylase
MY128449A (en) Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
BR0312232A (pt) Inibidores de caspases e seus usos
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BRPI0414792A (pt) derivados de ácido 4-(1h-indol-3-il-metilidenoaminóxi-propóxi)-benzóico e compostos relacionados como inibidores de pai-1 para o tratamento de enfraquecimento do sistema fibrinolìtico e de trombose
BR0316629A (pt) Uréias e carbamatos substituìdos
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
ATE338036T1 (de) Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
HUP0201284A2 (hu) Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére
BR0316163A (pt) Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho
WO2003099202A3 (en) Beta-secretase inhibitors
MY136367A (en) Treatment of cognitive failure

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.